Effect of COVID-19 on $^{18}$F-FDG PET/CT: Is there a need for considering COVID-19 status before planning $^{18}$F-FDG PET/CT for oncological evaluation?

Authors:

Anwin Joseph Kavanal, MD

Santosh Ranjan Jena, MBBS

Rajender Kumar, MD

Chandan Krushna Das, MD, DM

Sunil Kumar, MD

Bhagwant Rai Mittal, MD, DNB

Affiliation:

1. Department of Nuclear Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh-160012, India

2. Medical Oncology OPD, Department of Radiotherapy, Postgraduate Institute of Medical Education and Research, Chandigarh-160012, India

Corresponding Author:

Bhagwant Rai Mittal
Professor
Department of Nuclear Medicine and PET/CT
Postgraduate Institute of Medical Education and Research
Chandigarh-160012, India
Tel: +911722756722
Fax: +911722742858
Email: brmittal@yahoo.com
First Author:
Anwin Joseph Kavanal,
Senior Resident
Department of Nuclear Medicine
Postgraduate Institute of Medical Education and Research
Chandigarh, India- 160012
Tel: +91-9947384052
Fax: +91-172 2742858
Email: anwinjosephk@gmail.com

Disclaimer, if any: There is no conflict of interest

Word Counts of the manuscript: 831

Financial support for the work: There is no financial disclosure

Conflict of interest: None

Abbreviated Title: COVID-19 impact on PET/CT interpretation

Immediate Open Access: Creative Commons Attribution 4.0 International License (CC BY) allows users to share and adapt with attribution, excluding materials credited to previous publications.
License: https://creativecommons.org/licenses/by/4.0/.
Details: https://jnm.snmjournals.org/page/permissions.
ABSTRACT

Incidental detection of coronavirus disease-2019 (COVID-19) related lung changes in $^{18}$F-FDG PET/CT of oncology patients have been increasingly reported. Most of the case reports/series stressed the retrospective diagnosis of COVID-19 with the help of $^{18}$F-FDG PET/CT lung findings. In this case report, we introduce a different aspect of COVID-19 related lung changes in $^{18}$F-FDG PET/CT, interfering with the evaluation of metastatic lung lesions in patients with renal cell carcinoma.

**KEYWORDS:** COVID-19, $^{18}$F-FDG PET/CT, Lung metastasis, Response Evaluation, Renal cell carcinoma
INTRODUCTION

Various lung involvement patterns have been reported in $^{18}$F-FDG PET/CT of COVID-19 patients undergoing workup for various malignancies. The patterns range from $^{18}$F-FDG avid diffuse ground-glass opacities to $^{18}$F-FDG avid patchy consolidatory changes, with or without $^{18}$F-FDG avid mediastinal lymph nodes, depending on the imaging time from the onset of infection and other unknown factors [1-4]. COVID-19 infection was a retrospective diagnosis in most reported cases, after seeing the typical image findings in the $^{18}$F-FDG PET/CT [3-7]. Here, we present a different aspect of COVID-19 on $^{18}$F-FDG PET/CT causing interference with response assessment in a patient receiving chemotherapy for pulmonary metastasis from renal cell carcinoma.

CASE HISTORY

A 45 year-old-man, a known case of metastatic renal cell carcinoma, underwent cytoreduction nephrectomy followed by first-line chemotherapy with pembrolizumab and axitinib because of multiple cannonball metastases in the lungs. $^{18}$F-FDG PET/CT scan, at the end of treatment, showed disease progression in the form of an increase in the number and size of the lung nodules. Then he was started on second-line chemotherapy with Lenvatinib (oral, 18 mg daily) and Everolimus (oral, 5 mg daily). His interim $^{18}$F-FDG PET/CT (Figure 1) showed a favorable response (> 30% reduction in size and $^{18}$F-FDG avidity compared to baseline PET/CT) to second-line therapy, and he was continued on the same treatment. He was diagnosed with COVID-19 in May 2020 on evaluation for malaise and chills. He was managed conservatively with antibiotics, antipyretics, and multivitamins in a local hospital. He had no symptoms/signs suggestive of pneumonia and never required oxygen support during the 11 days course in the hospital. He was discharged from the hospital following a negative nucleic acid test one week before he was
scheduled for an $^{18}$F-FDG PET/CT scan at six months of chemotherapy to look for the response. The $^{18}$F-FDG PET/CT (Figure 2) showed $^{18}$F-FDG avid diffuse GGOs/patchy consolidatory changes in bilateral lung fields from apex to base, obscuring the metastatic lesions. The COVID-19 related lung changes obscured both anatomical and metabolic features of metastatic lesions, leading to difficulty in assessing response to treatment.

**DISCUSSION**

The $^{18}$F-FDG uptake in the GGOs in the background may add spill-in counts to the metastatic lesions causing a false high uptake in the metastatic lesions [8]. So, an accurate assessment of metabolic response was also not possible in this patient. The patient was advised to repeat the nucleic acid test because of $^{18}$F-FDG avidity in the GGOs/consolidatory changes and was found to be positive. The patient was advised to remain in home isolation again.

**CONCLUSION**

Thus, we have to consider this possible interference during this pandemic phase before scheduling patients for $^{18}$F-FDG PET/CT scan for various oncological purposes.
REFERENCES


Figure 1: (Column A) $^{18}$F-FDG PET/CT whole-body maximum-intensity projection image, (Column B) axial fused PET/CT images and (Column C) corresponding CT images showed variably $^{18}$F-FDG avid random nodules in both lung fields (SUVmax of hottest nodule 9.9).
Figure 2: (Column A) $^{18}$F-FDG PET/CT whole-body maximum-intensity projection image, (Column B) axial fused PET/CT images and (Column C) corresponding CT images showed $^{18}$F-FDG avid diffuse GGOs/patchy consolidatory changes in bilateral lung fields from apex to base obscuring the details of metastatic lesions (SUVmax of hottest nodule 7.8, SUV max of GGOs 7.3).